Literature DB >> 26990255

Correlation Between Appropriate Use Criteria and the Frequency of Subclinical Spread or Reconstruction With a Flap or Graft for Melanomas Treated With Mohs Surgery With Melanoma Antigen Recognized by T Cells 1 Immunostaining.

Jeremy R Etzkorn1, Joseph F Sobanko, Thuzar M Shin, Rosalie Elenitsas, Emily Y Chu, Joel M Gelfand, David J Margolis, Jason G Newman, Hayley Goldbach, Christopher J Miller.   

Abstract

BACKGROUND: Published appropriate use criteria (AUC) for Mohs micrographic surgery (MMS) for melanoma are based on consensus opinion.
OBJECTIVE: To evaluate whether published AUC identify melanomas for which MMS may benefit patients by detecting subclinical spread or confirming clear microscopic margins before flap or graft reconstruction.
MATERIALS AND METHODS: Retrospective cohort study of 591 melanomas in 556 patients evaluating the correlation between current AUC (anatomic location, recurrent status, and tumor stage) and subclinical spread or reconstruction with a flap or graft.
RESULTS: Anatomic location on the head, neck, genitalia, hands, feet, or pretibial leg was associated with a significantly higher frequency of subclinical spread (odds ratio (OR) 1.89, p = .0280) and flap or graft reconstruction (OR 10.3, p = .0001). Compared with primary lesions, recurrent melanomas had a higher frequency of subclinical spread (OR 1.78, p = .0104) and reconstruction with a flap or graft (OR 1.67, p = .0217). The frequencies of subclinical spread and flap or graft reconstruction did not differ between in situ and invasive melanomas.
CONCLUSION: Anatomic location and recurrent status are useful criteria to identify melanomas that may benefit from MMS. Tumor stage is not a useful criterion, as MMS has similar benefits for subsets of both invasive and in situ melanomas.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26990255      PMCID: PMC5340265          DOI: 10.1097/DSS.0000000000000693

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  16 in total

1.  AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.

Authors:  Suzanne M Connolly; Diane R Baker; Brett M Coldiron; Michael J Fazio; Paul A Storrs; Allison T Vidimos; Mark J Zalla; Jerry D Brewer; Wendy Smith Begolka; Timothy G Berger; Michael Bigby; Jean L Bolognia; David G Brodland; Scott Collins; Terrence A Cronin; Mark V Dahl; Jane M Grant-Kels; C William Hanke; George J Hruza; William D James; Clifford Warren Lober; Elizabeth I McBurney; Scott A Norton; Randall K Roenigk; Ronald G Wheeland; Oliver J Wisco
Journal:  J Am Acad Dermatol       Date:  2012-09-05       Impact factor: 11.527

2.  Preoperative expectations and values of patients undergoing Mohs micrographic surgery.

Authors:  Gary S Chuang; Brian C Leach; Lee Wheless; Pearon G Lang; Joel Cook
Journal:  Dermatol Surg       Date:  2011-02-22       Impact factor: 3.398

3.  Mohs micrographic excision of melanoma using immunostains.

Authors:  M J Zalla; K K Lim; D J Dicaudo; M M Gagnot
Journal:  Dermatol Surg       Date:  2000-08       Impact factor: 3.398

4.  Optimal management and challenges in treatment of upper facial melanoma.

Authors:  John P Berdahl; Barbara A Pockaj; Richard J Gray; William J Casey; John J Woog
Journal:  Ann Plast Surg       Date:  2006-12       Impact factor: 1.539

Review 5.  Importance of physical appearance in patients with skin cancer.

Authors:  Joseph F Sobanko; David B Sarwer; Zinta Zvargulis; Christopher J Miller
Journal:  Dermatol Surg       Date:  2015-02       Impact factor: 3.398

6.  Appearance is a function of the face.

Authors:  Gregory L Borah; Marlene K Rankin
Journal:  Plast Reconstr Surg       Date:  2010-03       Impact factor: 4.730

7.  Treatment of cutaneous melanoma of the face by Mohs micrographic surgery.

Authors:  Tasha N Bienert; Martin J Trotter; John P Arlette
Journal:  J Cutan Med Surg       Date:  2002-11-27       Impact factor: 2.092

8.  Cutaneous malignant melanoma of the head and neck.

Authors:  S R Fisher
Journal:  Laryngoscope       Date:  1989-08       Impact factor: 3.325

9.  Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study.

Authors:  L M Cohen; M W McCall; R H Zax
Journal:  Dermatol Surg       Date:  1998-06       Impact factor: 3.398

10.  Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: an update from the University of Minnesota.

Authors:  Jessica Newman; Matthew Beal; Sarah E Schram; Peter K Lee
Journal:  Dermatol Surg       Date:  2013-10-24       Impact factor: 3.398

View more
  1 in total

1.  Therapeutic strategies and potential implications of silver nanoparticles in the management of skin cancer.

Authors:  Shaloam Dasari; Clement G Yedjou; Robert T Brodell; Allison R Cruse; Paul B Tchounwou
Journal:  Nanotechnol Rev       Date:  2020-12-31       Impact factor: 7.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.